Risdiplam Under FDA Review & How the Lack of SMA Protein May Also Directly Contribute to SMA
Anticipation is growing as Roche/Genentech’s treatment risdiplam, the first oral medication to treat SMA, is under FDA review.
Also, SMA News Today’s multimedia associate, Price Wooldridge, discusses how the lack of SMA protein may also directly contribute to SMA.
Are you interested in learning more about spinal muscular atrophy? If so, please visit smanewstoday.com/What are your thoughts on this news? Let us know about it in the comment section below.
Sorry, there were no replies found.